Entolimod

Generic Name
Entolimod
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
951628-22-1
Unique Ingredient Identifier
R1UQ6D1ECM
Background

Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

Phase 2
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Entolimod
Drug: Influenza vaccine
First Posted Date
2019-11-25
Last Posted Date
2023-06-22
Lead Sponsor
Robert J. Pignolo
Target Recruit Count
61
Registration Number
NCT04176133
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Entolimod, an Adjuvant for Vaccine Augmentation

Early Phase 1
Completed
Conditions
Substance Use Disorders
Interventions
Drug: Entolimod
Biological: Td Vaccine
First Posted Date
2017-02-24
Last Posted Date
2020-09-01
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
40
Registration Number
NCT03063736
Locations
🇺🇸

Baylor College of Medicine, Houston, Texas, United States

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

First Posted Date
2012-11-19
Last Posted Date
2013-12-11
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT01728480

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

First Posted Date
2012-02-06
Last Posted Date
2022-07-22
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
25
Registration Number
NCT01527136
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy